A hydroquinone formulation with increased stability and decreased potential for irritation
| Autor: | Kelly Dong, Alan M. Walfield, Roger Grimson, Kenneth A. Smiles, Daniel B. Yarosh, Matthew T. Canning |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Adult
Male medicine.medical_specialty Dermatology Pharmacology medicine.disease_cause Antioxidants Statistics Nonparametric chemistry.chemical_compound Alkaloids Drug Stability Fluocinolone acetonide Hyperpigmentation medicine Humans Skin equivalent Patient compliance Cells Cultured High potential Melanins Hydroquinone Chemistry Ergothioneine Patch test Skin Irritancy Tests Hydroquinones Drug Combinations Quinazolines Dermatitis Irritant Melanocytes Female Dermatologic Agents medicine.symptom Irritation medicine.drug |
| Zdroj: | Journal of Cosmetic Dermatology. 6:83-88 |
| ISSN: | 1473-2165 1473-2130 |
| DOI: | 10.1111/j.1473-2165.2007.00301.x |
| Popis: | Summary Background Long-term treatment with a high-strength hydroquinone (HQ) cream (usually 4% HQ) is the mainstay therapy for hyperpigmentation disorders. Instability and high potential for irritancy hinders patient compliance. A new 4% HQ preparation has been designed with an innovative antioxidant for stability and a biomimetic of an herbal extract for skin calming. Aims To investigate the activity, stability, and irritancy of a new HQ cream. Methods To evaluate the new HQ cream in comparison with commercial 4% HQ creams for stability by temperature stress test, for irritancy by repeated-insult patch test on human subjects, and for lightening effect using the MelanoDerm™ B skin equivalent model. Results The new HQ is more resistant to browning and shows less irritancy than three commercially available 4% HQ products. It has comparable bleaching effect with faster onset than a 4% HQ product containing 0.05% tretinoin and 0.01% fluocinolone acetonide. Conclusion Based on its improved stability, lower irritancy, and activity in skin lightening, the new approach to the formulation of 4% HQ may improve therapeutic outcomes by improving patient compliance to dosing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|